Steris 10-Q 2026-09-30
STE · CIK 1757898 · Form 10-Q · Period ended September 30, 2026 · Filed November 5, 2026
Revenue rose 8.8% to $1.59 billion. Operating margin was 18.5%, against 18.2% a year earlier. Net income was $214 million.
8 sections, 227K characters. Original on sec.gov · ·
| Measure | Quarter ended Sep 30, 2026 | Quarter ended Sep 30, 2025 | Change |
|---|---|---|---|
| Revenue | $1.59B | $1.46B | +8.8% |
| Operating income | $294M | $266M | +10.7% |
| Net income | $214M | $192M | +11.4% |
| Cash and equivalents | $531M | n/a | n/a |
| Operating margin* | 18.5% | 18.2% | +0.3 pts |
From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.
Cover and table of contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-Q
(Mark One)
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2026
or
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934****For the transition period from _______ to _______ |
Commission File Number 001-38848
STERIS plc
(Exact name of registrant as specified in its charter)
| Ireland | 98-1455064 | |||||||||||||
| (State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) | |||||||||||||
| 70 Sir John Rogerson's Quay, | Dublin 2, | Ireland | D02 R296 | |||||||||||
| (Address of principal executive offices) | (Zip code) |
353 1 232 2000
(Registrant’s telephone number, including area code)
_______________________________________________
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
| Title of each class | Trading symbol(s) | Name of Exchange on Which Registered | ||||||
| Ordinary Shares, $0.001 par value | STE | New York Stock Exchange | ||||||
| 2.700% Senior Notes due 2031 | STE/31 | New York Stock Exchange | ||||||
| 3.750% Senior Notes due 2051 | STE/51 | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company,” in Rule 12b-2 of the Exchange Act.
| Large Accelerated Filer | ☒ | Accelerated Filer | ☐ | |||||||||||
| Non-Accelerated Filer | ☐ | Smaller Reporting Company | ☐ | |||||||||||
| Emerging Growth Company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
The number of ordinary shares outstanding as of November 3, 2026: 97,107,020
STERIS plc and Subsidiaries
Form 10-Q
Index
PART I—FINANCIAL INFORMATION
As used in this Quarterly Report on Form 10-Q, STERIS plc and its consolidated subsidiaries together are called “STERIS,” the “Company,” “we,” “us,” or “our,” unless otherwise noted.
Item 1. FINANCIAL STATEMENTS
STERIS PLC AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in millions, except par value)
| September 30, 2026 | March 31, 2026 | |||||||||||||
| (Unaudited) | ||||||||||||||
| Assets | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | 531.1 | $ | 439.6 | ||||||||||
| Accounts receivable (net of allowances of $31.8 and $27.3 respectively) | 1,005.2 | 1,092.8 | ||||||||||||
| Inventories, net | 737.0 | 631.8 | ||||||||||||
| Prepaid expenses and other current assets | 205.9 | 230.4 | ||||||||||||
| Total current assets | 2,479.2 | 2,394.6 | ||||||||||||
| Property, plant, and equipment, net | 2,187.6 | 2,161.2 | ||||||||||||
| Lease right-of-use assets, net | 156.0 | 155.2 | ||||||||||||
| Goodwill | 4,178.8 | 4,194.8 | ||||||||||||
| Intangibles, net | 1,497.0 | 1,620.0 | ||||||||||||
| Other assets | 215.0 | 211.4 | ||||||||||||
| Total assets | $ | 10,713.6 | $ | 10,737.2 | ||||||||||
| Liabilities and equity | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | 334.2 | $ | 338.8 | ||||||||||
| Accrued income taxes | 55.5 | 28.6 | ||||||||||||
| Accrued payroll and other related liabilities | 157.2 | 221.1 | ||||||||||||
| Short-term lease obligations | 37.2 | 35.8 | ||||||||||||
| Short-term indebtedness | 243.1 | 118.9 | ||||||||||||
| Accrued expenses and other | 380.6 | 401.9 | ||||||||||||
| Total current liabilities | 1,207.8 | 1,145.0 | ||||||||||||
| Long-term indebtedness | 1,650.3 | 1,812.8 | ||||||||||||
| Deferred income taxes, net | 389.7 | 390.7 | ||||||||||||
| Long-term lease obligations | 119.0 | 119.6 | ||||||||||||
| Other liabilities | 75.1 | 71.7 | ||||||||||||
| Total liabilities | $ | 3,441.9 | $ | 3,540.0 | ||||||||||
| Commitments and contingencies (see Note 9) | ||||||||||||||
| Ordinary shares, with $0.001 par value; 500.0 shares authorized; 97.1 and 97.8 ordinary shares issued and outstanding, respectively | 4,105.3 | 4,280.9 | ||||||||||||
| Retained earnings | 3,301.3 | 3,015.9 | ||||||||||||
| Accumulated other comprehensive loss | (149.3) | (113.1) | ||||||||||||
| Total shareholders’ equity | 7,257.3 | 7,183.6 | ||||||||||||
| Noncontrolling interests | 14.4 | 13.6 | ||||||||||||
| Total equity | 7,271.7 | 7,197.2 | ||||||||||||
| Total liabilities and equity | $ | 10,713.6 | $ | 10,737.2 |
See notes to consolidated financial statements.
STERIS PLC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(in millions, except per share amounts)
(Unaudited)
| Three Months Ended September 30, | Six Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Revenues: | ||||||||||||||||||||||||||
| Product | $ | 816.9 | $ | 745.4 | $ | 1,554.1 | $ | 1,435.9 | ||||||||||||||||||
| Service | 771.7 | 714.9 | 1,527.3 | 1,415.4 | ||||||||||||||||||||||
| Total revenues | 1,588.6 | 1,460.3 | 3,081.3 | 2,851.4 | ||||||||||||||||||||||
| Cost of revenues: | ||||||||||||||||||||||||||
| Product | 410.0 | 390.8 | 778.4 | 750.5 | ||||||||||||||||||||||
| Service | 467.7 | 423.6 | 907.9 | 827.0 | ||||||||||||||||||||||
| Total cost of revenues | 877.8 | 814.4 | 1,686.3 | 1,577.5 | ||||||||||||||||||||||
| Gross profit | 710.8 | 645.9 | 1,395.0 | 1,273.9 | ||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||
| Selling, general, and administrative | 366.0 | 349.7 | 735.7 | 703.6 | ||||||||||||||||||||||
| Research and development | 31.5 | 28.2 | 60.2 | 54.6 | ||||||||||||||||||||||
| Restructuring expenses | 19.1 | 2.2 | 19.1 | 3.9 | ||||||||||||||||||||||
| Total operating expenses | 416.6 | 380.1 | 814.9 | 762.1 | ||||||||||||||||||||||
| Income from operations | 294.3 | 265.8 | 580.1 | 511.8 | ||||||||||||||||||||||
| Non-operating expenses, net: | ||||||||||||||||||||||||||
| Interest expense | 11.2 | 14.9 | 26.9 | 30.7 | ||||||||||||||||||||||
| Interest and miscellaneous income | (3.6) | (2.4) | (6.8) | (4.1) | ||||||||||||||||||||||
| Other (income) expense, net | (1.3) | 0.2 | (1.6) | 0.3 | ||||||||||||||||||||||
| Total non-operating expenses, net | 6.2 | 12.7 | 18.5 | 26.8 | ||||||||||||||||||||||
| Income before income tax expense | 288.0 | 253.1 | 561.5 | 485.0 | ||||||||||||||||||||||
| Income tax expense | 73.9 | 60.6 | 146.4 | 114.5 | ||||||||||||||||||||||
| Net income | 214.1 | 192.5 | 415.1 | 370.4 | ||||||||||||||||||||||
| Less: Net income attributable to noncontrolling interests | 0.4 | 0.6 | 1.3 | 1.3 | ||||||||||||||||||||||
| Net income attributable to shareholders | $ | 213.7 | $ | 191.9 | $ | 413.8 | $ | 369.2 | ||||||||||||||||||
| Net income per share attributable to shareholders: | ||||||||||||||||||||||||||
| Basic | $ | 2.20 | $ | 1.95 | $ | 4.25 | $ | 3.75 | ||||||||||||||||||
| Diluted | $ | 2.19 | $ | 1.94 | $ | 4.23 | $ | 3.74 | ||||||||||||||||||
Showing the first 8K of 119K characters. Open the full section
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Introduction
In Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), we explain the general financial condition and the results of operations for STERIS and its subsidiaries including:
-
what factors affect our business;
-
what our earnings and costs were in each period presented;
-
why those earnings and costs were different from prior periods;
-
where our earnings came from;
-
how this affects our overall financial condition;
-
what our expenditures for capital projects were; and
-
where cash is expected to come from to fund future debt principal repayments, growth outside of core operations, repurchases of shares, cash dividends and future working capital needs.
As you read the MD&A, it may be helpful to refer to information in our consolidated financial statements contained herein, which present the results of our operations for the first six months of fiscal 2027 and fiscal 2026. It may also be helpful to refer to our Annual Report on Form 10-K for the year ended March 31, 2026, which was filed with the Securities and Exchange Commission ("SEC") on May 29, 2026, including information in Item 1, "Business," Part I, Item 1A, "Risk Factors," and Note 9 to our consolidated financial statements titled, "Commitments and Contingencies," and Part II, Item 1A, "Risk Factors" of this Quarterly Report, for a discussion of some of the matters that can adversely affect our business and results of operations.
In the MD&A, we analyze and explain the period-over-period changes in the specific line items in the Consolidated Statements of Income. This information, discussion, and analysis may be important to you in making decisions about your investments in STERIS.
Financial Measures
In the following sections of the MD&A, we may, at times, refer to a financial measure that is not required to be presented in the consolidated financial statements under accounting principles generally accepted in the United States ("U.S. GAAP"). We sometimes use the following financial measure in the context of this report: backlog. We define backlog as the amount of unfilled capital equipment purchase orders (excluding freight) at a point in time. We use this figure as a measure to assist in the projection of short-term financial results and inventory requirements.
We, at times, may also refer to financial measures which are considered to be “non-GAAP financial measures” under SEC rules. We have presented these financial measures because we believe that meaningful analysis of our financial performance is enhanced by an understanding of certain additional factors underlying that performance. These financial measures should not be considered an alternative to measures required by accounting principles generally accepted in the United States. Our calculations of these measures may differ from calculations of similar measures used by other companies, and you should be careful when comparing these financial measures to those of other companies. Additional information regarding these financial measures, including reconciliations of each non-GAAP financial measure, is available in the subsection of MD&A titled, "Non-GAAP Financial Measures."
Revenues – Defined
As required by Regulation S-X, we separately present revenues generated as either Product revenues or Service revenues on our Consolidated Statements of Income for each period presented. When we discuss revenues, we may, at times, refer to revenues summarized differently than the Regulation S-X requirements. The terminology, definitions, and applications of terms that we use to describe revenues may be different from terms used by other companies. We use the following terms to describe revenues:
-
Revenues – Our revenues are presented net of sales returns and allowances.
-
Product Revenues – We define Product revenues as revenues generated from sales of consumable and capital equipment products.
-
Service Revenues – We define Service revenues as revenues generated from parts and labor associated with the maintenance, repair, and installation of our capital equipment. Service revenues also include outsourced reprocessing services and instrument and scope repairs, as well as revenues generated from contract sterilization and laboratory services offered through our Applied Sterilization Technologies ("AST") segment.
-
Capital Equipment Revenues – We define capital equipment revenues as revenues generated from sales of capital equipment, which includes steam and gas sterilizers, low temperature liquid chemical sterilant processing systems, automated endoscope reprocessors, pure steam/water systems, surgical lights and tables, and integrated operating rooms.
-
Consumable Revenues – We define consumable revenues as revenues generated from sales of the consumable family of products, which includes dedicated consumables used in our capital equipment, gastrointestinal endoscopy accessories, instruments and tools, sterility assurance products, barrier protection solutions, and cleaning consumables.
-
Recurring Revenues – We define recurring revenues as revenues generated from sales of consumable products and Service revenues.
GENERAL COMPANY OVERVIEW AND EXECUTIVE SUMMARY
STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. We offer our Customers a unique mix of innovative products and services. These include: consumable products, such as detergents, endoscopy accessories, barrier products, instruments and tools; services, including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair, laboratory testing, and outsourced reprocessing; capital equipment, such as sterilizers, surgical tables, and automated endoscope reprocessors; and connectivity solutions such as operating room integration.
We operate and report our financial information in three reportable business segments: Healthcare, AST, and Life Sciences. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. We describe our business segments in Note 10 to our consolidated financial statements titled, "Business Segment Information."
The bulk of our revenues are derived from healthcare, medical device and pharmaceutical Customers. Much of the growth in these industries is driven by the aging of the population throughout the world, as an increasing number of individuals are entering their prime healthcare consumption years, and is dependent upon advancement in healthcare delivery, acceptance of new technologies, government policies, and general economic conditions.
In addition, there is increased demand for medical procedures, including preventive screenings such as endoscopies and colonoscopies; and a desire by our Customers to operate more efficiently, all of which are driving increased demand for many of our products and services.
Acquisitions. During the first six months of fiscal 2027, we completed three tuck-in acquisitions, recorded at fair value, which continued to expand our product and service offerings in the Healthcare segment. Total aggregate consideration was approximately $17.3 million, including deferred consideration and the fair value of potential contingent consideration.
Acquisition and integration expenses totaled $4.0 million and $5.5 million for the three and six months ended September 30, 2026, respectively. Acquisition and integration expenses totaled $1.3 million and $1.8 million for the three and six months ended September 30, 2025, respectively. Acquisition and integration expenses reported in the Selling, general and administrative expenses and Cost of revenues lines of our Consolidated Statements of I
Showing the first 8K of 85K characters. Open the full section
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
In the ordinary course of business, we are subject to interest rate, currency, and commodity risks. Information related to these risks and our management of these exposures is included in Part II, Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” in our Annual Report on Form 10-K for the year ended March 31, 2026, which was filed with the SEC on May 29, 2026. Our exposures to market risks have not changed materially since March 31, 2026.
Fluctuations in currency rates could affect our revenues, Cost of revenues and income from operations and could result in currency exchange gains and losses. During the second quarter of fiscal 2027, we held forward foreign currency contracts to hedge a portion of our expected non-U.S. dollar-denominated earnings against our reporting currency, the U.S. dollar. We did not elect hedge accounting for these forward currency contracts; however, we may seek to apply hedge accounting in future scenarios. As a result, we may experience volatility due to (i) the timing mismatch of unrealized hedge gains or losses versus recognition of the underlying hedged earnings, and (ii) the impact of unrealized and realized hedge gains or losses being reported in selling, general and administrative expenses, whereas the offsetting economic gains and losses of the underlying hedged earnings are reported in the various line items of our Consolidated Statements of Income.
We also enter into foreign currency forward contracts to hedge monetary assets and liabilities denominated in foreign currencies, including inter-company transactions. We do not use derivative financial instruments for speculative purposes. At September 30, 2026, we held net foreign currency forward contracts to sell 29.3 million euros, 7.0 million Australian dollars, and 7.0 million New Zealand dollars, and to buy 125.0 million Mexican pesos and 7.0 million British pounds.
We are dependent on basic raw materials, sub-assemblies, components, and other supplies used in our operations. Our financial results could be affected by the availability and changes in prices of these materials. The costs of these materials can rise suddenly and result in significantly higher costs of production. Where appropriate, we enter into long-term supply contracts as a basis to guarantee a reliable supply. We may also enter into commodity swap contracts to hedge price changes in a certain commodity that impacts raw materials included in our Cost of revenues. At September 30, 2026, we held commodity swap contracts to buy 0.3 million pounds of nickel.
Item 4. CONTROLS AND PROCEDURES
Under the supervision of and with the participation of our management, including the Principal Executive Officer (“PEO”) and Principal Financial Officer (“PFO”), we evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of the end of the period covered by this Quarterly Report. Based on that evaluation, including the assessment and input of our management, the PEO and PFO concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures were effective.
There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act, that occurred during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II—OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Information regarding our legal proceedings is included in this Form 10-Q in Note 9 to our consolidated financial statements titled, "Commitments and Contingencies" and in Item 7 of Part II, titled “Management's Discussion and Analysis of Financial Condition and Results of Operations," of our Annual Report on Form 10-K for the year ended March 31, 2026, which was filed with the SEC on May 29, 2026.
Item 1A. RISK FACTORS
For a complete discussion of the Company's risk factors, you should carefully review the risk factors included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2026, which was filed with the SEC on May 29, 2026. There have been no material changes to the risk factors set forth in Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026, except with regard to the risk factors set forth below related to the Xodus Medical Acquisition.
The Purchase Agreement may be terminated in accordance with its terms and the Xodus Medical Acquisition may not be completed.
The Xodus Medical Acquisition is subject to a number of conditions, including, among others: the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and receipt of any required approvals under other applicable antitrust laws; the absence of governmental orders or laws prohibiting closing; the accuracy of each party’s representations and warranties (subject to specified materiality and material adverse effect standards); and each party’s performance of its obligations in all material respects. These conditions may not be fulfilled in a timely manner or at all, and governmental authorities may condition their approval on divestitures or other remedies, any of which could delay or prevent the closing, increase costs or reduce the anticipated benefits of the Xodus Medical Acquisition.
Either STERIS or the sellers may terminate the Purchase Agreement if the Xodus Medical Acquisition has not been completed by July 12, 2027 (automatically extended to January 11, 2028 if required regulatory approvals remain outstanding) and in certain other circumstances. If the Xodus Medical Acquisition is not completed for any reason, STERIS will have incurred significant transaction-related costs and devoted substantial management time and resources, without realizing any of the anticipated benefits, which could materially and adversely affect STERIS’s business, financial condition, results of operations and the market price of its ordinary shares.
Uncertainty about the Xodus Medical Acquisition may adversely affect the businesses of STERIS and Xodus Medical while the Xodus Medical Acquisition is pending.
Uncertainty about the effect of the Xodus Medical Acquisition may cause key employees to leave and Customers, suppliers and other business partners to delay decisions or seek to change or terminate their relationships with STERIS or Xodus Medical. In addition, the Purchase Agreement restricts Xodus Medical from taking certain actions without STERIS’s consent before the closing, which may prevent Xodus Medical from pursuing business opportunities. STERIS and Xodus Medical may also become subject to litigation or regulatory inquiries relating to the Xodus Medical Acquisition, which could result in additional costs, delay the closing or divert management’s attention.
STERIS expects to incur substantial additional indebtedness to finance the Xodus Medical Acquisition, which could adversely affect its business and financial condition.
As of September 30, 2026, STERIS had approximately $1.9 billion of indebtedness outstanding, and it expects to incur approximately $2.0 billion of additional indebtedness to finance the Xodus Medical Acquisition. This additional indebtedness will heighten the risks described under “Our debt level or access to credit markets may limit our financial and business flexibility” in STERIS’s Annual Report on Form 10-K. The terms of any permanent financing will depend on market conditions at the time and may be less favorable than anticipated, and the agreements governing it are expected to contain covenants that may restrict STERIS’s operations. If STERIS is unable to obtain permanent financing on acceptable terms, it may be required to draw on the bridge facility, which would likely carry higher costs and shorter maturities. Furthermore, STERIS’s ability to service this indebtedness will depend in part on Xodus Medical achieving its anticipated results and Xodus Medical’s actual results may differ materially from expectations.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES
On May 3, 2023 our Board of Directors authorized a share repurchase program (the "Outgoing Repurchase Program") for the purchase of up to $500.0 million aggregate purchase amount (exclusive of fees, commissions, and other charges), with no specified expiration date. Under the Outgoing Repurchase Program, the Company could repurchase its shares from time to time through open market purchases, including 10b5-1 plans. It also permitted share repurchases to be activated, suspended or discontinued at any time.
On May 5, 2026, our Board of Directors terminated the Outgoing Repurchase Program and authorized a new share repurchase program (the "New Repurchase Program") for the purchase of up to $1,000.0 million aggregate purchase amount (exclusive of fees, commissions, and other charges).
Under the New Repurchase Program, we may repurchase our shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. There is no limitation to the number of shares that can be repurchased in a year and there is no expiration date for the New Repurchase Program.
During the first six months of fiscal 2027, we repurchased 0.9 million of our ordinary shares for the aggregate purchase amount of $200.0 million (exclusive of fees, commissions, and other charges) pursuant to authorizations, under the New Repurchase Program. During the first six months of fiscal 2026, we repurchased 0.4 million of our ordinary shares for the aggregate amount of $100.0 million (exclusive of fees, commissions, and other charges) pursuant to authorizations, under the Outgoing Repurchase Program.
During the first six months of fiscal 2027, we obtained 0.1 million of our ordinary shares in the aggregate purchase amount of $15.9 million in connection with share-based compensation award programs. During the first six months of fiscal 2026, we obtained 0.1 million of our ordinary shares in the aggregate amount of $11.1 million in connection with share-based compensation award programs.
As of September 30, 2026, there was $800.0 million aggregate purchase amount (exclusive of fees, commissions, and other charges) of remaining availability under the New Repurchase Program.
The following table summarizes the ordinary shares repurchase activity during the second quarter of fiscal 2027 under our ordinary share repurchase program:
| (in millions, except per share data) | Total Number of Shares Purchased | Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans | Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plans at Period End | ||||||||||||||||||||||
| July 1-31 | — | $ | — | — | $ | 900.0 | ||||||||||||||||||||
| August 1-31 | 0.4 | 235.46 | 0.4 | 805.8 | ||||||||||||||||||||||
| September 1-30 | — | 230.21 | — | 800.0 | ||||||||||||||||||||||
| Total | 0.4 | (1) | $ | 235.14 | (1) | 0.4 | $ | 800.0 |
(1) Does not include five shares purchased during the quarter at an average price of $216.76 per share by the STERIS Corporation 401(k) Plan on behalf of an executive officer of the Company who may be deemed to be an affiliated purchaser.
Item 5. OTHER INFORMATION
During the three months ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" as such terms are defined under Item 408 of Regulation S-K, except as follows:
On August 13, 2026, Daniel A. Carestio, President and Chief Executive Officer of the Company, adopted a trading arrangement for the sale of the Company’s ordinary shares that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act (such plan, a “Rule 10b5-1 Trading Plan”). Mr. Carestio’s Rule 10b5-1 Trading Plan, which expires July 14, 2028, provides for the sale of up to 31,980 ordinary shares pursuant to the terms of such plan. Certain of the subject shares are currently unvested awards. The actual number of ordinary shares available to be sold under the Rule 10b5-1 Trading Plan related to unvested awards will be calculated at the time of vesting of such equity awards after withholding to satisfy tax obligations.
On September 4, 2026, Cary L. Majors, Senior Vice President and President, Healthcare of the Company, adopted a Rule 10b5-1 Trading Plan. Mr. Majors’s Rule 10b5-1 Trading Plan, which expires September 7, 2027, provides for the sale of up to 5,231 ordinary shares and the exercise and sale of up to 24,712 stock options pursuant to the terms of such plan.
Item 6. EXHIBITS
Exhibits required by Item 601 of Regulation S-K
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| STERIS plc | ||
| /s/ KAREN L. BURTON | ||
| Karen L. Burton | ||
| Senior Vice President and Chief Financial Officer | ||
| November 5, 2026 |